ArticleFrontiers in pharmacology2025
Targeting lipogenesis promotes the synergistic effect of the selective HDAC6 inhibitor ITF3756 with bortezomib in colon cancer cells.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Histone deacetylases in cancer metabolic reprogramming.Experimental & molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Selective histone deacetylase (HDAC) inhibition has recently emerged as a promising strategy for antitumor targeted therapy. HDAC6 is a member of the HDAC family that mainly deacetylates non-histone proteins, regulating multiple cellular functions, including lipogenesis. HDAC6 is associated with the development and progression of colorectal cancer (CRC) and is related to CRC poor prognosis. This paper evaluates the effects of the selective HDAC6 inhibitor ITF3756 in CRC cells in combination with bortezomib (BTZ), a proteasome inhibitor that promotes lipogenesis. Method: Cell viability was evaluated by MTT assay. Lipid content and quantification were estimated by ORO staining and triacylglycerol spectrophotometric kit. Apoptosis was detected by Annexin V/PI and cell cycle distribution analysis. Western blot was used to detect proteins involved in lipogenesis and apoptosis. SREBP-1 was knocked down by a specific siRNA. Results: The selective HDAC6 inhibitor ITF3756 reduced the viability of HCT116 and HT29 colon cancer cells and promoted lipogenesis. Considering the involvement of HDAC6 in controlling lipid metabolism, ITF3756 was combined with bortezomib (BTZ), a proteasome inhibitor that promotes lipid accumulation. Subtoxic doses of ITF3756 and BTZ exerted a synergistic apoptotic effect in HCT116 cells and caused mTOR phosphorylation, SREBP activation and PPARg increase, thus enhancing lipid production. The ITF3756/BTZ combination was less efficacious in HT29 cells that displayed a high basal level of lipid droplets. Diacylglycerol acyltransferase 1 (DGAT-1) and 2 (DGAT-2) inhibitors blocked lipogenesis and increased the effect of the ITF3756/BTZ combination in both cell lines, thereby suggesting that lipogenesis represents a defensive response. This hypothesis was confirmed by SREBP-1 silencing, which also potentiated the antitumor efficacy of the ITF3756/BTZ combination in HCT116 cells. Discussion: Overall, these results reveal a particular antitumor efficacy of the selective HDAC6 inhibitor in combination with BTZ in colon cancer cells and suggest that inhibiting lipogenesis is a useful tool to further increase the synergistic effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.